EcoDrugPlus

Cholinergic Receptor, Nicotinic Alpha 4

Ensembl ID : ENSXETG00000044956
Gene Symbol: CHRNA4
8 Enzyme and pathways 5 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Nicotinic Alpha 7

Ensembl ID : ENSXETG00000016395
Gene Symbol: CHRNA7
6 Enzyme and pathways 5 View Cross-references
246 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Nicotinic Beta 4

Ensembl ID : ENSXETG00000033968
Gene Symbol: CHRNB4
12 Enzyme and pathways 5 View Cross-references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinesterase

Ensembl ID : ENSXETG00000008731
Gene Symbol: LOC100494295
3 View Cross-references
129 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor 10

Ensembl ID : ENSXETG00000025492
Gene Symbol: F10
11 Enzyme and pathways 5 View Cross-references
239 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor 12 (Hageman Factor)

Ensembl ID : ENSXETG00000007245
Gene Symbol: F12
3 Enzyme and pathways 5 View Cross-references
185 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor 2 (Thrombin) Receptor

Ensembl ID : ENSXETG00000003338
Gene Symbol: F2R
7 Enzyme and pathways 5 View Cross-references
327 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor 7 (Serum Prothrombin Conversion Accelerator)

Ensembl ID : ENSXETG00000001932
Gene Symbol: F7
10 Enzyme and pathways 5 View Cross-references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor Iii (Thromboplastin, Tissue Factor)

Ensembl ID : ENSXETG00000030465
Gene Symbol: F3
3 Enzyme and pathways 5 View Cross-references
243 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coiled-Coil Domain Containing 6

Ensembl ID : ENSXETG00000003119
Gene Symbol: CCDC6
5 View Cross-references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Collagenase 3

Ensembl ID : ENSXETG00000040194
Gene Symbol: LOC100489108
4 View Cross-references
161 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Collagenase 3-Like

Ensembl ID : ENSXETG00000038461
Gene Symbol: LOC116408899
3 View Cross-references
161 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).